Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-05-06 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document text is extremely short (300 characters) and contains no substantive content, financial data, or detailed information. It appears to be a placeholder or header with company identifiers and omitted images. There is no indication of a full report or detailed announcement. Given the brevity and lack of content, this is likely a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2022-05-06 English
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2022 ,inter alia, to consider and approve the audited standalone and consolidated ....
Regulatory Filings Classification · 95% confidence The document is a short notice dated May 3, 2022, addressed to stock exchanges, informing about a forthcoming Board of Directors meeting scheduled for May 18, 2022. The purpose of the meeting is to consider and take on record the audited standalone and consolidated financial results for the quarter and year ended March 31, 2022, and to recommend a dividend if any. The document does not contain any financial data or results itself but is a notification of an upcoming event where such results will be discussed and possibly announced. The length is only 1101 characters, indicating it is a brief announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about an upcoming board meeting and financial results consideration, not the results or report themselves.
2022-05-03 English
Board Meeting — Dividend/Financial results/Other business matters
Regulatory Filings Classification · 90% confidence The document text is extremely short (122 characters) and contains no substantive content, financial data, or any descriptive text. It only mentions omitted pictures and no report or announcement details are present. Given the lack of content, it cannot be classified as any specific report or announcement type. According to the rules, such minimal content defaults to Regulatory Filings (RNS) as a fallback category.
2022-05-03 English
Press Release
Regulatory Filings Classification · 95% confidence The document text is extremely short (305 characters) and contains no substantive content, financial data, or detailed information. It only includes placeholders for images and some stock exchange ticker symbols. There is no indication of any report, announcement, or detailed filing. Given the lack of content and the nature of the text, it does not fit any specific detailed filing category. According to the rules, such minimal content with no report or announcement details defaults to Regulatory Filings (RNS) as a fallback category.
2022-04-29 English
Lupin Launches its Reference Laboratory in Guwahati, Assam.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new Reference Laboratory by Lupin Diagnostics in Guwahati, Assam. It is addressed to stock exchanges and references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content focuses on business expansion and operational updates rather than financial results, management changes, or regulatory filings. The document is relatively short (4782 characters) and serves as a disclosure announcement rather than a detailed report or financial filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2022-04-29 English
Lupin Appoints Diana Amador-Toro as Senior Vice President, Global Compliance.
Board/Management Information Classification · 100% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing the appointment of Ms. Diana Amador-Toro as Senior Vice President, Global Compliance. It is a formal announcement of a change in senior management. The document does not contain financial data, audit information, or detailed reports, but rather an official notification of a management appointment. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3815 characters, which is consistent with a typical announcement rather than a full report.
2022-04-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.